BPC-157 + TB-500 (10mg)
A blend of BPC-157 (5 mg) and TB-500 (5 mg) in one 10 mg vial, designed for synergistic tissue healing. BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that enhances angiogenesis and growth factors (VEGF, PDGF), while TB-500 (Thymosin Beta-4) promotes cell migration by regulating actin and reduces scar tissue formation. It is administered subcutaneously once daily with gradual titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
BPC-157 is a synthetic 15-amino acid peptide corresponding to a portion of human gastric protein. It enhances VEGF/PDGF signaling and nitric oxide (NO) pathways, increasing angiogenesis and fibroblast migration. Preclinical models show accelerated healing of intestine, tendons, ligaments, and muscle injuries. TB-500 (Thymosin Beta-4) is a 43-amino acid peptide that regulates actin, allowing for more efficient cell migration and reduced fibrosis. It also promotes angiogenesis, anti-apoptosis, and reduced scar tissue. The combination simultaneously targets local repair (BPC-157) and systemic tissue regeneration (TB-500) for faster, higher-quality healing.
Quick Start
- Reconstitution: Add 2.0 mL of bacteriostatic water → 5 mg/mL (2.5 mg/mL per peptide).
- Typical Daily Range: 500–1,000 mcg total once daily (gradual titration).
- Storage: Lyophilized: freeze at −20 °C · after reconstitution: refrigerate at 2–8 °C · use within 4 weeks · avoid freeze-thaw cycles.
8-Week Titration Protocol (2 mL = 5 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 10 Units (0.10 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 15 Units (0.15 mL) |
| Weeks 5–8 | 1,000 mcg (1.0 mg) | 20 Units (0.20 mL) |
Studies report administration once daily subcutaneously. The dosing is gradually increased every 2 weeks. A typical cycle is 4–8 weeks, followed by a 2–4 week break. Injecting near the injured tissue may improve outcomes according to preclinical studies.
Reconstitution Steps
- Draw 2.0 mL of bacteriostatic water with a sterile syringe (ideally 3 mL with a 21–23 gauge needle).
- Slowly inject into the side wall of the vial, letting the water run down the glass · avoid foaming (do not spray directly onto the powder).
- Gently swirl or rotate until fully dissolved (do not shake vigorously—this damages peptide bonds).
- Mark the reconstitution date and concentration (5 mg/mL) on the vial · refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Objective: Synergistic tissue healing — angiogenesis via BPC-157 + cell migration via TB-500.
- Schedule: Daily subcutaneous injections for 4–8 weeks, followed by a 2–4 week break.
- Storage: Lyophilized frozen · reconstituted refrigerated · avoid freeze-thaw cycles.
Dosing Protocol
- Initiation: 500 mcg daily (10 units) · this low dose assesses individual tolerance.
- Titration: 750 mcg daily (15 units) for weeks 3–4.
- Target: 1,000 mcg daily (20 units) for weeks 5–8.
- Cycle Duration: 4–8 weeks on, 2–4 weeks off · injecting near the injured tissue may improve the effect.
- Break between cycles: After the cycle, a 2–4 week break is recommended before repeating. The break helps prevent tolerance (tachyphylaxis) and restore natural healing mechanisms.
Washout & Cycle Restart
When can I restart?
After the cycle, a 2–4 week break is recommended before repeating. The break helps prevent tolerance (tachyphylaxis) and restore natural healing mechanisms.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions · minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C · use within 4 weeks · avoid freeze-thaw.
- Allow frozen vials to reach room temperature before opening to prevent moisture condensation.
Important Notes
- Injecting near the site of injury may improve local results according to preclinical data.
- Human clinical data for this specific combination remains limited · decisions should be made with a healthcare professional.
Potential Benefits & Side Effects
Potential Benefits:
- Accelerated healing of tendons, muscles, joints, and skin according to preclinical data.
- Reduction of inflammation and pain through modulation of inflammatory cytokines.
- Improved tissue quality with less fibrosis and scar tissue.
- Synergistic angiogenesis — increased blood flow to injured tissues.
- Generally very well tolerated in research models with no significant toxicity.
Potential Side Effects:
- Potential mild injection site reaction (redness, itching, transient discomfort).
- Rarely, slight dizziness or a feeling of warmth immediately after injection.
- Human clinical data remains preliminary · long-term safety has not been fully established.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007References
- HSS Journal (PMC) — BPC-157 in orthopaedic sports medicine: a systematic review (2025)
View Source - Annals of the NY Academy of Sciences — Thymosin β4 and tissue repair: a multifunctional peptide
View Source - Expert Opinion on Biological Therapy — Thymosin β4 as a regenerative agent
View Source - Frontiers in Endocrinology (2021) — Progress in the function and application of Thymosin β4
View Source - Current Pharmaceutical Design (PMC) — BPC 157: a stable gastric pentadecapeptide with healing properties
View Source
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval (extensive preclinical research)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →